Trials / Completed
CompletedNCT05585112
Articaine 4% Versus Lidocaine 2% for Local Anesthesia of MIH-affected Maxillary Molars
Comparative Study of Articaine 4% Versus Lidocaine 2% in Local Anesthesia and Permanent Maxillary First Molars Affected by MIH.
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 26 (actual)
- Sponsor
- Tishreen University · Academic / Other
- Sex
- All
- Age
- 6 Years – 12 Years
- Healthy volunteers
- Accepted
Summary
Comparison of injection pain with lidocaine and articaine. Comparison of the efficacy of lidocaine and articaine during treatment of MIH- maxillary molars. Design: A randomized, controlled, crossover, Triple-blinding clinical study including twenty six cooperative children, aged 6-12years old
Detailed description
Background and Aims: Some dentists have difficulty obtaining effective anesthesia when treating MIH molars. There are no studies comparing the effectiveness of lidocaine and articaine in MIH-maxillary molars. Design: A randomized, controlled, crossover, Triple-blinding clinical study including twenty six cooperative children , aged 6-12 years old. Each child was randomly assigned to either articaine 4% or lidocaine 2% in their first session with the second solution being used at the second session.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Lidocaine 2% | The child will be injected with lidocaine 2%,after that the treatment will be completed , Pain during injection and treatment will be assessed using the FLACC scale and pain after injection and treatment will be evaluated using the Wong-Baker faces pain rating scale |
| DRUG | Articaine 4% | The child will be injected with 4% Articaine, after that the treatment will be completed , Pain during injection and treatment will be assessed using the FLACC scale and Wong-Baker faces pain rating scale |
Timeline
- Start date
- 2022-10-17
- Primary completion
- 2022-12-05
- Completion
- 2022-12-25
- First posted
- 2022-10-18
- Last updated
- 2023-05-03
Locations
1 site across 1 country: Syria
Source: ClinicalTrials.gov record NCT05585112. Inclusion in this directory is not an endorsement.